CD19 and neoplasm: In conclusion, our comparative analysis of seven anti‐CD19 CAR designs using UCB‐derived NK cells indicates that the first‐generation CAR construct with CD8 TMD‐CD3ζ SD offers optimal anti‐tumour efficacy.